We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Signs Contract to Deliver Shipment of Four Million Allplex SARS-CoV-2/FluA/FluB/RSV Assay to Brazil

By LabMedica International staff writers
Posted on 24 Feb 2022

Seegene, Inc. More...

(Seoul, Korea) has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.

Since January 2022, Brazil has battled a 'twindemic,' a rapid surge in both Flu A and COVID-19 infections due to the rapid spread of the Omicron variant. More seriously, new daily cases of COVID-19 have recently exceeded 280,000 cases, which is the highest figure since the first outbreak of the pandemic. While the country has been seeking to accelerate its quarantine efforts, there is a growing demand for COVID-19 tests as well. In response, Seegene will deliver a shipment of four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses including COVID-19, Flu A/B as well as RSV in a single test. This assay is expected to be the optimized solution in Brazil where they are experiencing a rapid surge in both COVID-19 and Flu A cases.

Meanwhile, in January this year, Seegene introduced Allplex SARS-CoV-2 Fast PCR Assay, a new assay optimized for mass testing. This assay can deliver PCR results in just 60 minutes enabling large-scale laboratories to easily scale up the testing volume up to three times without additional instruments. The launch of the new assay is a response to the rapid spread of the latest Omicron variant, globally. The new assay is expected to be the optimized choice for large-scale laboratories and help them immediately expand the testing capacity.

"Seegene is uniquely positioned to respond to the growing global need for COVID-19 and flu testing and we are fully prepared to supply global inventory to help countries around the world as they fight for everyday life to return," said Ho Yi, Chief Sales and Marketing Officer of Seegene.

Related Links:
Seegene, Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.